In addition, our in vivo study demonstrated that the combination of esomeprazole and pirfenidone is more effective in suppressing lung fibrosis than esomeprazole or pirfenidone monotherapy as shown by reduction in fibrosis and αSMA expression (Figs. 7, 8, 9). Here, ACTA1 is linked to pulmonary fibrosis.